Premium
In vitro and in vivo antifungal activity of cetrimide (cetyltrimethyl ammonium bromide) against fungal keratitis caused by Fusarium solani
Author(s) -
Mahmoud Yehia A.G.
Publication year - 2007
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2006.01313.x
Subject(s) - cetrimide , keratitis , fungal keratitis , in vivo , microbiology and biotechnology , medicine , cornea , fusarium solani , pharmacology , chemistry , ophthalmology , biology , dentistry , chlorhexidine
Summary Mycotic keratitis is a devastating eye infection acquired after eye injury. Cetrimide at 15 and 20 mg ml −1 produced no surviving Fusarium solani growth with minimal inhibitory concentration value of 0.10 mg ml −1 . Topical administration of three drops (0.3 ml) of cetrimide aqueous solution of 10 mg ml −1 at pH 6.4 three times daily succeeded to cure human severe resistant F. solani keratitis in a time course of <3 weeks, and with complete healing after 6 weeks. Cetrimide‐treated rabbit corneas section appeared with normal compact epithelium and endothelium with no vacuolation in Descemet's endothelial complex: an indication that cetrimide has no significant toxic effects. So, cetrimide at 10 mg ml −1 may be effective and safe topical therapy in patients with mycotic keratitis, especially F. solani ulcers. Currently, there is no antimycotic drug with a good corneal penetration, which is safe and has a fungicidal activity.